Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.50 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.50 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.50 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146161 | 0.85 | HSD11B1 (0.59) | HSD11B1HTR6LMNATSHRABCC9 | |
| SCHEMBL28541788 | 0.83 | HSD11B1 (0.61) | HSD11B1LMNAABCC9ABCC8KCNJ11 | |
| SCHEMBL3157029 | 0.83 | HSD11B1 (0.57) | HSD11B1HTR6LMNAABCC9ABCC8 | |
| SCHEMBL28539914 | 0.83 | HSD11B1 (0.61) | HSD11B1LMNACYP3A4CYP2C9TSHR | |
| SCHEMBL9713772 | 0.83 | HTR6 (0.50) | HSD11B1HTR6LMNACYP3A4CYP2C9 | |
| SCHEMBL30468568 | 0.81 | ALDH1A1 (0.62) | HSD11B1LMNATSHRABCC9ABCC8 | |
| SCHEMBL3790370 | 0.81 | HTR6 (0.69) | HTR6LMNACYP3A4CYP2C9TSHR | |
| SCHEMBL8514629 | 0.81 | ALDH1A1 (0.62) | HSD11B1LMNATSHRABCC9ABCC8 | |
| SCHEMBL10692275 | 0.80 | ALDH1A1 (0.57) | HSD11B1HTR6LMNACYP3A4CYP2C9 | |
| SCHEMBL5284219 | 0.79 | HSD11B1 (0.53) | HSD11B1HTR6LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012134-A1 | Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists | CURTIS NEIL ROY | 2009-01-08 | — | — | US | disclosed |
| EP-1866300-A1 | ARYLSULFONYL BENZOFUSED HETEROCYCLES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006100519-A1 | ARYLSULFONYL BENZOFUSED HETEROCYCLES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| US-5684198-A | N-ARYL-2-HYDROXYPROPANAMIDES | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1997-11-04 | — | — | US | disclosed |
| US-5567735-A | CELL POTASSIUM CHANNEL MODULATOR FOR TREATING ASTHMA | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-22 | — | — | US | disclosed |
| US-5565477-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| US-5565465-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| EP-0524781-B1 | Therapeutic amides | ZENECA LTD (GB) | 1996-03-27 | — | — | EP | disclosed |
| US-5474999-A | Useful in treatment of urinary incontinence | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-12-12 | — | — | US | disclosed |
| US-5382598-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-01-17 | — | — | US | disclosed |
| US-5272163-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| EP-0524781-A1 | Therapeutic amides | ZENECA LIMITED (GB) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012134-A1 | Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists | HTR2A, HTR2C, HTR2B | HSD11B1 2234/4885HTR6 14/4885LMNA 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.